Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

被引：1
|
作者：
Muggia, F.
Safra, T.
Borgato, L.
Gandhi, A.
Mancinc, G.
Gabizon, A.
Liebes, L.
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] IOV, Padua, Italy
[4] SZMC, Jerusalem, Israel
[5] NYU, Inst Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
    Andreopoulou, E.
    Gaiotti, D.
    Kim, E.
    Downey, A.
    Mirchandani, D.
    Hamilton, A.
    Jacobs, Allan
    Curtin, John
    Muggia, F.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 716 - 721
  • [32] Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older
    Vergote, I.
    Vermorken, J.
    Pujade-Lauraine, E.
    Monk, B.
    Lisyanskaya, A.
    Rolski, J.
    Vasanthan, S.
    Santabarbara, P.
    Bayever, E.
    Poveda, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 458 - 458
  • [33] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] EARLY CA-125 RESPONSE PATTERN IN PATIENTS WITH RECURRENT OVARIAN CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)
    Oaknin, A.
    Barretina, P.
    Jimenez, L.
    Perez, X.
    Velasco, M.
    Alsina, M.
    Pardo, B.
    Brunet, J.
    Germa, J. R.
    Beltran, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 215 - 215
  • [35] Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Lisyanskaya, Alla S.
    Makhson, Anatoly N.
    Rolski, Janusz
    Gorbounova, Vera A.
    Ghatage, Prafull
    Bidzinski, Mariusz
    Shen, Keng
    Ngan, Hextan Yuen-Sheung
    Vergote, Ignace B.
    Nam, Joo-Hyun
    Park, Youn Choi
    Lebedinsky, Claudia A.
    Poveda, Andres M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3107 - 3114
  • [36] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [37] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [38] Technetium-99m Sulfur Colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of PEGylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (EOC)
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Ivanovic, Marija
    Walsh, Mark D.
    Caron, Whitney P.
    Song, Gina
    Whitlow, Ann B.
    Newman, Suzanne E.
    La-Beck, Nihn
    Kowalsky, Richard J.
    Zamboni, Beth A.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Le, LindaVan
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William C.
    PHARMACOTHERAPY, 2012, 32 (10): : E310 - E310
  • [39] Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer
    Song, Gina
    Tarrant, Teresa K.
    White, Taylor F.
    Barrow, David A.
    Santos, Charlene M.
    Timoshchenko, Roman G.
    Hanna, Suzan K.
    Ramanathan, Ramesh K.
    Lee, Craig R.
    Bae-Jump, Victoria L.
    Gehrig, Paola A.
    Zamboni, William C.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2015, 11 (07) : 1797 - 1807
  • [40] Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer
    Keng Shen~1Beihua Kong~2Yunong Gao~3Lingying Wu~4Ziting Li~5Yile Chen~6Mengda Li~7Yongliang Gao~8Ding Ma~9Zhilan Peng~(10)1 Peking Union Medical College Hospital
    Clinical Oncology and Cancer Research, 2009, (06) : 387 - 393
12345